Metformin ameliorates animal models of dermatitis.
Soo Young ChoiChanmi LeeMin-Jeong HeoYeong Min ChoiIn-Sook AnSeunghee BaeSungkwan AnJin Hyuk JungPublished in: Inflammopharmacology (2020)
Metformin, a potent AMPK activator is the most commonly used drug for diabetes. According to recent reports, metformin lowers the risk of diabetic complications and inflammatory diseases. We found the expression levels of AMPK subunits including PRKAA1, PRKAA2, PRKAB1 and PRKAB2 are decreased in skin biopsies of dermatitis patients from multiple datasets. Interestingly, metformin treatment ameliorates dermatitis symptom in animal model of dermatitis using O-tetradecanoylphorbol-13-acetate (TPA). Especially, the levels of epidermis and dermis thickness were decreased by metformin. We found NFκB activity as well as of gene expression associated with collagen synthesis are attenuated by metformin treatment. These results suggest that metformin treatment alleviates animal model of dermatitis.
Keyphrases
- gene expression
- type diabetes
- cardiovascular disease
- poor prognosis
- mouse model
- end stage renal disease
- dna methylation
- newly diagnosed
- skeletal muscle
- immune response
- nuclear factor
- signaling pathway
- combination therapy
- weight loss
- binding protein
- soft tissue
- single cell
- drug induced
- rna seq
- adverse drug
- tissue engineering